Huons Global subsidiary Huons to absorb Huons Lab... 24.2% dilution but R&D synergy expected; schedule delayed for parent shareholder protection
Huons (KOSDAQ-listed) decided to absorb its unlisted subsidiary Huons Lab. Merger ratio 1:0.4256943, issuing 3,825,373 new shares (24.20%) to Huons Lab shareholders.
Purpose: transition from generic-focused business to build a full biopharmaceutical value chain and strengthen R&D capabilities for global competitiveness.
Merger price: Huons at KRW 34,062 (market price), Huons Lab at KRW 14,500 (intrinsic value: asset value KRW 808 + earnings value KRW 23,628 weighted). External evaluator Ichon Accounting Corp. deemed fair.
Huons Lab had negative equity of -KRW 1.8B and net loss of -KRW 10.2B in 2025. Turnaround expected via merger synergies.
No change in control. Huons Lab's 817,617 redeemable convertible preferred shares to be converted into common shares before merger (resulting in 905,420 common shares).
Schedule delayed for parent company Huons Global's shareholder consultation: dissent notice period Aug 6-20, 2026, shareholder meeting Aug 21, appraisal rights exercise Aug 21-Sep 11.
Appraisal right price: KRW 32,886 (average of volume-weighted average prices over 2 months, 1 month, 1 week). Merger may be terminated if total appraisal amount exceeds KRW 30B for Huons or KRW 4B for Huons Lab.
Merger date: Sep 23, 2026; new shares listing: Oct 12, 2026. Appraisal rights void if merger fails.
[AI Final Analysis]The merger entails near-term dilution (24.2%) and Huons Lab's loss-making status, but long-term R&D synergies and biopharma pipeline enhancement warrant a neutral view. Schedule delay is positive for minority protection, but shareholder opposition remains a risk.
KOSDAQ Filing Information
Filing: [Correction of Description] Report on Major Matters (Decision on Company Merger)(Major Management Matters of Subsidiary)